XIFIN's relationship with our clients is one of partnership & advocacy. From our relentless pursuit of best practices to our representation on standards committees & industry associations, the measure of our success is in the improvement of our clients financial performance.
Client Success
XIFIN's relationship with our clients is one of partnership & advocacy. From our relentless pursuit of best practices to our representation on standards committees & industry associations, the measure of our success is in the improvement of our clients financial performance.
Without exception, XIFIN's clients have increased their cash collections, and reduced bad debt and days sales outstanding.
AI BioTech, LLC"Implementing RCM solutions that will help us navigate the reimbursement and regulatory complexities of the molecular diagnostics market is critical to drive rapid company growth. XIFIN was the clear choice because the company has a solid reputation for achieving results, powerful web service technology, and a leadership team recognized for change advocacy and reform in the molecular DX and diagnostic services market. I am confident that our partnership with XIFIN will provide the framework we need to strategically manage our operations and drive growth and profitability." -Bill Miller, CEO |
|
AMS Reference Lab"There was so much dropping through the cracks. I knew it. I just didn’t know how to find it and I didn’t know how to do anything to make it better." -Janet Kaufman, Business Manager |
|
Clarient"We've seen a 35% improvement in our cash collections over the short two year period that we've had the XIFIN product up and running and validated. It's been a very important tool for us to really improve the financial health of our company." -Ron Andrews, CEO |
|
LabWest/Westcliff"I've been impressed with their ability to provide a comprehensive AR system that is user friendly and provides the flexibility in information reporting formats to meet our needs." -Richard Nicholson, Former CEO |
|
Myriad Genetics"We went live with XIFIN in 2007 and we are continually getting more efficiencies and our stats continue to get better." -Todd Ogaard, Vice President |
|
NICL Laboratories"There was definitely a return on cash and that was return on all the old stuff that just sat there, unbilled, because of missing information; because I couldn’t find it." -Joel Welder, Comptroller |
|
North Shore LIJ"Not only is XIFIN a business partner, they’re a colleague in what we do. It’s transparent to us. XIFIN is part of North Shore LIJ in what we do every day." -Richard Tesoriero, Finance Director, North Shore LIJ |
|
Physicians Reference Laboratory"Before XIFIN, things that were going into bad debt were both contractual adjustments as well as true bad debt. Now, we have a better indicator from a financial statement perspective how we’re really performing…and it’s been a huge advantage to us." -Dan Spragle, Former EVP and COO |
|
Piedmont Medical Laboratory"XIFIN's Web-based solution provided instantaneous updates, decision support, comprehensive reporting and other important automation functionality." -Joe Skrisson, CEO |
|
Sonora Quest Laboratories"Given the complexity of healthcare billing, especially in the lab industry, SaaS will help us leverage external expertise without replicating resources in house. By utilizing the rules-based engines inherent in the XIFIN software, we will see efficiencies in our process, improvements in our reimbursement and revenue cycle, plus enhancements in our reporting capabilities. With these improvements, we expect to see an immediate return on our SaaS expenditures." -David Lutich, CFO |
|
US Labs"The process gave us the personal assurance that we were getting good data in and out of the system with correct bills, codes, and a definitive trust in the net revenue number." -Judd Jessup, CEO |
|
Laboratory Revenue Cycle Management Best Practices
Download Now
A CEO's Guide to Increasing Laboratory Valuation
Download Now
A CEO's Guide to Molecular Diagnostic Reimbursement
Download Now
© Copyright 2013 XIFIN, Inc. All Rights Reserved.
